Know Cancer

forgot password

A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Chemotherapy and Radiotherapy

Phase 2
18 Years
Open (Enrolling)
Oral Mucositis

Thank you

Trial Information

A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Chemotherapy and Radiotherapy

Inclusion Criteria:

- Willing and able to understand and sign an informed consent form (ICF) for the study
approved by the Investigator's local or a central Institutional Review Board (IRB)

- Have recently diagnosed, pathologically confirmed, non-metastatic SCC of the oral
cavity, oropharynx, hypopharynx, or larynx that will be treated with ChemoRT as
first-line treatment; subjects with a history of surgical management are eligible

- Have a plan to receive a continuous course of conventional external beam irradiation
delivered by intensity-modulated radiotherapy (IMRT) as single daily fractions of 2.0
to 2.2 Gy, with a cumulative radiation dose between 50 and 72 Gy. Planned radiation
treatment fields must include at least 2 oral sites (buccal mucosa, floor of oral
cavity, tongue, or soft palate), with each site receiving ≥ 50 Gy

- Have a plan to receive a standard cisplatin CT regimen administered tri-weekly (80 to
100 mg/m2, on Days 0, 21, and 42) or weekly (30 to 40 mg/m2)

- Have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

- Have adequate hematopoietic, hepatic, and renal function at the screening visit:

- Hematopoietic function

- Hemoglobin ≥ 10 g/dL

- Absolute neutrophil counts (ANC) ≥ 1,500 cells/mm3

- Platelet count ≥ 100 × 109/L

- Hepatic function

- Total bilirubin < 1.5 times the upper-normal limit (ULN)

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.0
times the ULN

- Renal function: Serum creatinine concentration ≤ 2 mg/dL; if result is ≥ 1.4
mg/dL and ≤ 2.0 mg/dL, a 24-hour urinary creatinine clearance test must be
performed by the site's local laboratory. To be eligible for the study, a
subject must demonstrate a 24-hour urinary creatinine clearance ≥ 50 mL/min

- Have a negative serum pregnancy test if a woman is of childbearing potential

- Agree to use medically acceptable methods of birth control during study participation
and for 30 days following the last CTM treatment if a woman is of childbearing

- Males or females aged 18 years or older.

Exclusion Criteria:

- Tumor of the lips, sinuses, salivary glands, nasopharynx, or unknown primary tumor

- Metastatic disease (M1) Stage IV C

- Prior radiation to the head and neck

- Plan to be treated with cetuximab (Erbitux®)

- Have undergone induction CT

- History of other malignant tumors, excluding non-melanoma skin cancer or curatively
excised in situ cervical carcinoma

- Have had a major surgical procedure, other than for HNC, or significant traumatic
injury within 4 weeks prior to the initiation of RT; anticipation of need for a major
surgical procedure during the study

- Active infectious disease, excluding oral candidiasis

- Have OM at the baseline visit

- Have a diagnosis of autoimmune disease requiring chronic immunosuppression

- Known seropositivity for HIV, HBV, or HCV

- Prior use of SCV 07

- Have used any investigational agent within 30 days of randomization

- Are pregnant or breastfeeding

- Known allergies or intolerance to cisplatin

- Unable to give informed consent or comply with study requirements, including
completing the subject diary and QOL instruments

- Have any other condition or therapy that, in the opinion of the Investigator, would
make the subject unsuitable for the study or unable to comply with follow-up visits.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Outcome Measure:


Outcome Description:

The primary objective of the study is to evaluate the efficacy of SCV 07 in modifying the course of oral mucositis (OM) in subjects with head and neck cancer (HNC) receiving concurrent ChemoRT.

Outcome Time Frame:

June 2012

Safety Issue:


Principal Investigator

Israel Rios, MD

Investigator Role:

Study Director

Investigator Affiliation:

SciClone Pharmaceuticals


United States: Food and Drug Administration

Study ID:




Start Date:

December 2010

Completion Date:

May 2013

Related Keywords:

  • Oral Mucositis
  • Oral Mucositis
  • Head and Neck
  • Head and Neck Neoplasms
  • Mucositis
  • Stomatitis
  • Neoplasms by Site
  • Neoplasms
  • Gastroenteritis
  • Gastrointestinal Diseases
  • Digestive System Diseases
  • Mouth Diseases
  • Stomatognathic Diseases
  • SCV-07
  • Head and Neck Neoplasms
  • Stomatitis
  • Mucositis



Medical University of South Carolina Charleston, South Carolina  29425-0721
Mary Bird Perkins Cancer Center Baton Rouge, Louisiana  70809
New York Methodist Hospital Brooklyn, New York  11215-3609
Beth Israel Medical Center New York, New York  10003
Virginia Mason Medical Center Seattle, Washington  98111
University of Arkansas for Medical Sciences Little Rock, Arkansas  72205
Long Island Jewish Medical Center New Hyde Park, New York  11040
Summa Health System Akron, Ohio  44312
Montefiore Medical Center Bronx, New York  10467-2490
Mount Nittany Medical Center State College, Pennsylvania  16803
City of Hope National Medical Center Los Angeles, California  91010
Comprehensive Blood and Cancer Center Bakersfield, California  93309
Washington Cancer Institute Washington, District of Columbia  20010
University of Minnesota Minneapolis, Minnesota  55455
Temple University Hospital Philadelphia, Pennsylvania  19140
Arizona Oncology Services Foundation Phoenix, Arizona  85013
Arizona Clinical Research Center Tucson, Arizona  85712
Helen F. Graham Cancer Center Newark, Delaware  19713
Lakeland Regional Cancer Center Lakeland, Florida  33805
Providence Portland Medical Center Portland, Oregon  97213-3635
University of Louisville Louisville, Kentucky  40202
Louisiana State University Health Sciences Center Shreveport, Louisiana  71130
University of Kentucky Lexington, Kentucky  40536-0098
Yale University School Of Medicine New Haven, Connecticut  06520
University of Maryland Medical Center Baltimore, Maryland  21201-1595
Wake Forest University Health Sciences Winston-Salem, North Carolina  27157
Wheeling Hospital Wheeling, West Virginia  26003
The Nebraska Medical Center Omaha, Nebraska  68198
University of Oklahoma Health Science Center Oklahoma City, Oklahoma  73104
The Christ Hospital Cancer Center Cincinnati, Ohio  45219
St. Agnes Hospital Baltimore, Maryland  21229
Washington University in St. Louis St. Louis, Missouri  63110
Tyler Hematology Oncology Tyler, Texas  75701
Arizona Center for Cancer Care Glendale, Arizona  85306
Lake County Oncology and Hematology The Villages, Florida  32159
Disney Family Cancer Center Burbank, California  91505
VA Long Beach Health System Long Beach, California  90822
Pomona Valley Hospital Pomona, California  91767
The Whittingham Cancer Center, Norwalk Hospital Norwalk, Connecticut  06856
The University of Illinois at Chicago Chicago, Illinois  60612
St. John's Cancer Center Anderson, Indiana  46016
Southcoast Hospital Group Fairhaven, Massachusetts  02719
Gershenson Radiation Detroit, Michigan  48201
Veterans Administration NJ Health Care System East Orange, New Jersey  07018
Rochester University Medical Center Rochester, New York  14642
Memorial Hospital of Rhode Island Cancer Center Pawtucket, Rhode Island  02860
Cookeville Regional Cancer Center Cookeville, Tennessee  38501
Kirkland Cancer Center/Jackson Madison County General Hospital Jackson, Tennessee  38301
Medical College of Wisconson Milwaukee, Wisconsin  53226